Company intelligence / Profile preview

Otonomy, Inc.

San Diego, California, United Statesotonomy-aviation.com ↗

Ownership: Private
Employees: ~200
Development stage: Phase 2

Overview

The company experienced multiple clinical failures, including OTO-413 for hearing loss and OTO-313 for tinnitus in 2022, leading to the company's dissolution. Previously had FDA-approved product Otiprio.

Therapeutic areas: OtolaryngologyNeurologyInfectious Diseases
Modalities: Small moleculesdrug delivery technology
Industry: Biotech

Drug pipeline

8 assets

gacyclidine

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Otonomy, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otonomy, Inc..

Explore the full profile